

SUPPLEMENTARY TABLE

Supplementary Table 1. Oligos used in the study.

Name	Sequences 5' to 3'
circACTA2-F	GGCAACTCGTAACTCTTCTCAAGGG
circACTA2-R	CTCTGTCTGGATCGGTGGCTCC
circACTA2-F	GGAATGATTTGGAAAAGAACTGAAGGC
circACTA2-R	CTCTGTCTGGATCGGTGGCTCC
GAPDH-F	AAAGCCTGCCGGTGACTAAC
GAPDH-R	AGGAAAAGCATCACCCGGAG
CDK4 mRNA-F	GTGTATGGGGCCGTAGGAAC
CDK4 mRNA-R	CAGTCGCCTCAGTAAAGCCA
cyclin E1-F	CCATCATGCCGAGGGAGC
cyclin E1-R	TTGCCCAGCTCAGTACAGG
p16-F	CCGAATAGTTACGGTCGGAGG
p16-R	AATCGGGGATGTCTGAGGGA
p21-F	AGTCAGTTCCTTGTGGAGCC
p21-R	CATTAGCGCATCACAGTCGC
CDK4-probe1	CATGTCCACAGGTGTTGCATATGTGGACTG
CDK4-probe2	CCATGGCAGCCACTCCATTGCTCACTCCGG
cyclin E1-probe1	CTCCCTGTGAAGTTTATAGACTTCACACAC
cyclin E1-probe2	CTCTGCAATCTGTATAAAGATTTGCTGGGG
cyclin D1-probe1	GTCACACTTGATCACTCTGGAGAGGAAGCG
cyclin D1-probe2	CCTCCACTGGATGGTTTGTCACTGGATGGT